Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: Novel CYP17 inhibitors for the treatment of prostate cancer

Journal of Medicinal Chemistry

Volumn 51, Issue 16, 2008, Pages 5009-5018

  Pinto Bazurco Mendieta, Mariano A E ^a   Negri, Matthias ^a   Jagusch, Carsten ^a   Müller Vieira, Ursula ^b   Lauterbach, Thomas ^c   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Pharmacelsus CRO   (Germany)

^c Schwarz Pharma AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORO 4 [5 (PYRIDIN 4 YL) 5,6,7,8 TETRAHYDRONAPHTHALEN 2 YL]PHENOL HYDROBROMIDE; 2 FLUORO 4 [5 (PYRIDIN 4 YL) 7,8 DIHYDRONAPHTHALEN 2 YL]PHENOL HYDROBROMIDE; 3 [5 (4 FLUOROPHENYL) 2,3 DIHYDRO 1H INDEN 1 YL]PYRIDINE; 3 [5 (4 FLUOROPHENYL) 3H INDEN 1 YL]PYRIDINE; 4 [5 (4 FLUOROPHENYL) 2,3 DIHYDRO 1H INDEN 1 YL]PYRIDINE; 4 [5 (4 FLUOROPHENYL) 3,4 DIHYDRONAPHTHALEN 1 YL]PYRIDINE; 4 [5 (4 FLUOROPHENYL) 3H INDEN 1 YL]PYRIDINE; 4 [5 (4 METHOXYPHENYL) 3H INDEN 1 YL]PYRIDINE; 4 [5 (PYRIDIN 4 YL) 5,6,7,8 TETRAHYDRONAPHTHALEN 2 YL]BENZENE 1,2 DIOL HYDROBROMIDE; 4 [5 (PYRIDIN 4 YL) 7,8 DIHYDRONAPHTHALEN 2 YL]BENZENE 1,2 DIOL HYDROBROMIDE; 4 [6 (3,4 DIFLUOROPHENYL) 1,2,3,4 TETRAHYDRONAPHTHALEN 1 YL]PYRIDINE; 4 [6 (3,4 DIFLUOROPHENYL) 3,4 DIHYDRONAPHTHALEN 1 YL]PYRIDINE; 4 [6 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRONAPHTHALEN 1 YL]PYRIDINE; 5 (3 FLUORO 4 METHOXYPHENYL) 1 (PYRIDIN 4 YL) 2,3 DIHYDRO 1H INDEN 1 OL; 5 (4 FLUOROPHENYL) 1 (PYRIDIN 3 YL) 2,3 DIHYDRO 1H INDEN 1 OL; 5 (4 FLUOROPHENYL) 1 (PYRIDIN 4 YL) 2,3 DIHYDRO 1H INDEN 1 OL; 5 (4 METHOXYPHENYL) 1 (PYRIDIN 4 YL) 2,3 DIHYDRO 1H INDEN OL; 6 (3 FLUORO 4 METHOXYPHENYL) 1 (PYRIDIN 4 YL) 1,2,3,4 TETRAHYDRONAPHTHALEN 1 OL; 6 (3,4 DIFLUOROPHENYL) 1 (PYRIDIN 4 YL) 1,2,3,4 TETRAHYDRONAPHTHALEN 1 OL; 6 (4 FLUOROPHENYL) 1 (PYRIDIN 4 YL) 1,2,3,4 TETRAHYDRONAPHTHALEN 1 OL; ABIRATERONE; ALDOSTERONE SYNTHASE; CYTOCHROME P450; CYTOCHROME P450 11B1; CYTOCHROME P450 17 INHIBITOR; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; IC 50; MOLECULAR MODEL; PROSTATE CANCER;

ANDROSTENOLS; BIPHENYL COMPOUNDS; ENZYME INHIBITORS; HUMANS; MALE; MODELS, MOLECULAR; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 50249131899     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800355c     Document Type: Article

References (50)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. Ca - Cancer J. Clin. 2008, 58, 71-96.
2. Pomerantz, M.; Kantoff, P. Advances in the treatment of prostate cancer. Annu. Rev. Med. 2007, 58, 205-220.
3. Huhtaniemi, I.; Nikula, H.; Parvinen, M.; Rannikko, S. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer. Am. J. Clin. Oncol 1988, 11 (Suppl. 1), S11-S15.
4. Forti, G.; Salerno, R.; Moneti, G.; Zoppi, S.; Fiorelli, G.; Marinon, T.; Natali, A.; Constantini, A.; Serio, M.; Martini, L.; Motta, M. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J. Clin. Endocrinol. Metab. 1989, 68, 461-468.
5. Labrie, F.; Dupont, A.; Belanger, A.; Cusan, L.; Lacourciere, Y.; Monfette, G.; Laberge, J. G.; Emond, J. P.; Fazekas, A. T.; Raynaud, J. P.; Husson, J. M. New hormonal therapy in prostatic carcinoma: combined treatment with LHRH agonist and an antiandrogen. Clin. Invest. Med. 1982, 5, 267-275.
6. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trial. Lancet 2000, 355, 1491-1498.
7. Hara, T.; Miyazaki, J.; Araki, H.; Yamaoka, M.; Kanzaki, N.; Kusaka, M.; Miyamoto, M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003, 63, 149-153.
8. (a) Harris, K. A.; Weinberg, V.; Bok, R. A.; Kakefuda, M.; Small, E. J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J. Urol. 2002, 168, 542-545.
9. (b) Eklund, J.; Kozloff, M.; Vlamakis, J.; Starr, A.; Mariott, M.; Gallot, L.; Jovanovic, B.; Schilder, L.; Robin, E.; Pins, M.; Bergan, R. C. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer 2006, 106, 2459-2465.
10. Small, E. J.; Halabi, S.; Dawson, N. A.; Stadler, W. M.; Rini, B. I.; Picus, J.; Gable, P.; Torti, F. M.; Kaplan, E.; Vogelzang, N. J. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J. Clin. Oncol. 2004, 22, 1025-1033.
11. 17,20-lyase (cytochrome P45017α) with resistance to esterase hydrolysis. J. Med. Chem. 1995, 38, 4191-4197.
12. 17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J. Med. Chem. 1996, 39, 3319-3323.
13. 17α inhibitors. J. Steroid Biochem. Mol. Biol. 1997, 60, 347-351.
14. 17,20-lyase inhibitors. Bioorg. Med. Chem. 2004, 12, 2251-2273.
15. 17,20-lyase inhibitors. Bioorg. Med. Chem. 2004, 12, 4313-4336.
16. 17α). Bioorg. Med. Chem. Lett. 2006, 16, 4011-4015.
17. (a) Njar, V. C. O.; Hector, M.; Hartmann, R. W. 20-Amino and 20,21-aziridinyl pregnene steroids: development of potent inhibitors of 17 alpha-hydroxylase/C17,20-lyase (P450 17). Bioorg. Med. Chem. 1996, 4, 1447-1453.
18. (b) Hartmann, R. W.; Hector, M.; Haidar, S.; Ehmer, P.; Reichert, W.; Jose, J. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2. J. Med. Chem. 2000, 43, 4266-4277.
19. (c) Hartmann, R. W.; Hector, M.; Wachall, B. G.; Paluszcak, A.; Palzer, M.; Huch, V.; Veith, M. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alpha-hydroxylase/C17-20-lyase (P450 17). J. Med. Chem. 2000, 43, 4437-4445.
20. (d) Haidar, S.; Hartmann, R. W. C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17alpha-hydroxylase-C17, 20-lyase: synthesis and biological evaluation. Arch. Pharm. 2002, 335, 526-534.
21. (a) Sergejew, T.; Hartmann, R. W. Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha). J. Enzyme Inhib. 1994, 8, 113-122.
22. (b) Hartmann, R. W.; Wächter, G. A.; Sergejew, T.; Würtz, R.; Düerkop, J. 4,5-Dihydro-3-(2-pyrazinyl)naphtho[1,2-c]pyrazole: a potent and selective inhibitor of steroid-17 alpha-hydroxylase-C17,20-lyase (P450 17). Arch. Pharm. (Weinheim, Ger.) 1995, 328, 573-575.
23. (c) Wächter, G. A.; Hartmann, R. W.; Sergejew, T.; Grün, G. L.; Ledergerber, D. Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17. J. Med. Chem. 1996, 39, 834-841.
24. (d) Zhuang, Y.; Hartmann, R. W. Synthesis and evaluation of azole-substituted 2-aryl-6-methoxy-3,4-dihydronaphthalenes and -naphthalenes as inhibitors of 17α-hydroxylase-C17,20-lyase (P450 17). Arch. Pharm. 1999, 332, 25-30.
25. (e) Hartmann, R. W.; Ehmer, P. B.; Haidar, S.; Hector, M.; Jose, J.; Klein, C. D. P.; Seidel, S. B.; Sergejew, T.; Wachall, B. G.; Wächter, G. A.; Zhuang, Y. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure. Arch. Pharm. 2002, 335, 119-128.
26. (f) Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 2003, 84, 555-562.
27. (g) Clement, O. O.; Freeman, C. M.; Hartmann, R. W.; Paluszcak, A.; Handratta, V. D.; Vasaitis, T. S.; Brodie, A. M. H.; Njar, V. C. O. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J. Med. Chem. 2003, 46, 2345-2351.
28. (h) Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Jagusch, C; Hille, U. E.; Müller-Vieira, U.; Schmidt, D.; Hansen, K.; Hartmann, R. W. Bioorg. Med. Chem. Lett. 2008, 18, 267-273.
29. (i) Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Hu, Q.; Hille, U.; Jagusch, C.; Müller-Vieira, U.; Jahn-Hoffmann, K.; Schmidt, D.; Lauterrbach, T.; Hartmann, R. W. CYP17 inhibitors. Annulations of additional rings in methyleneimidazole substituted biphenyls: synthesis, biological evaluation and modelling. Arch. Pharm. Life Sci., in press.
30. (a) Wachall, B. G.; Hector, M.; Zhuang, Y.; Hartmann, R. W. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer. Bioorg. Med. Chem. 1999, 7, 1913-1924.
31. (b) Zhuang, Y.; Wachall, B. G.; Hartmann, R. W. Novel imidazolyl and triazolyl substituted biphenyl compounds: synthesis and evaluation as nonsteroidal inhibitors of human 17alpha-hydroxylase-C17, 20-lyase (P450 17). Bioorg. Med. Chem. 2000, 8, 1245-1252.
32. (c) Leroux, F.; Hutschenreuter, T.; Charrière, C.; Scopelliti, R.; Hartmann, R. W. N-(4-Biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substitution. Helv. Chim. Acta 2003, 86, 2671-2686.
33. (d) Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme. J. Enzyme Inhib. Med. Chem. 2004, 18, 17-32.
34. (e) Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-Bazurco Mendieta, M. A. E.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure. Bioorg. Med. Chem. 2008, 16, 1992-2010.
35. (f) Hu, Q.; Negri, M.; Jahn-Hoffmann, K.; Zhuang, Y.; Olgen, S.; Bartels, M.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Hartmann, R. W. Synthesis, in vitro and in vivo evaluation and modelling studies of substituted imidazolyl methylene biphenyls as CYP17 inhibitors. Bioorg. Med. Chem., in press.
36. (a) Madan, R. A.; Arlen, P. M. IDrugs 2006, 9, 49-55.
37. (b) Attard, G.; Reids, A.; Molife, R.; Thompson, E.; Barrett, M.; Lee, G.; Parker, C.; Dearnaley, D.; De Bono, J. S. Abiraterone, an oral, irreversible, CYP450C17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer (CRCP) patients (PTS). Ann. Oncol. 2007, 18 (Suppl. 9), 173.
38. Haidar, S.; Hartmann, R. W. Enzyme Inhibitor Examples for the Treatment of Prostate Tumor. In Enzymes and their Inhibition. Drug Development; Smith, H. J., Simons, C., Eds.; CRC Press: Boca Raton, FL, 2005; pp 241-253.
39. Schenkman, J. B.; Sligar, S. G.; Cinti, D. L. Substrate interaction with cytochrome P-450. Pharmacol. Ther. 1981, 12, 43-71.
40. Manga, N.; Duffy, J. C.; Rowe, P. H.; Cronin, M. T. D. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ. Res. 2005, 16, 43-61.
41. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
42. Ehmer, P. B.; Jose, J.; Hartmann, R. W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase-C(17,20)- lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli. J. Steroid Biochem. Mol. Biol. 2000, 75, 57-63.
43. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Müller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179.
44. Auchus, R. J.; Miller, W. L. Molecular modeling of human P450cl7 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol. Endocrinol. 1999, 13, 1169-1182.
45. (a) Denner, K.; Bernhardt, R. Inhibition Studies of Steroid Conversions Mediated by Human CYP11B1 and CYP11B2 Expressed in Cell Cultures. In Oxygen Homeostasis and Its Dynamics; Ishimura, Y., Shimada, H., Suematsu, M., Eds.; Springer-Verlag: Heidelberg, Germany, 1998; pp 231-236.
46. (b) Böttner, B.; Denner, K.; Bernhardt, R. Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. Eur. J. Biochem. 1998, 252, 458-466.
47. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
48. Halgren, T. A. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 1999, 20, 730-748.
49. (a) Bottegoni, G.; Cavalli, A.; Recanatini, M. A comparative study on the application of hierarchical-agglomerative clustering approaches to organize outputs of reiterated docking runs. J. Chem. Inf. Model. 2006, 46, 852-862.
50. (b) Bottegoni, G.; Rocchia, W.; Recanatini, M.; Cavalli, A. AClAP, autonomous hierarchical agglomerative cluster analysis based protocol to partition conformational datasets. Bioinformatics 2006, 22, 58-65.